Table 1.
Author | Age (years) | Structural heart disease | Gestation | Management | Outcome |
---|---|---|---|---|---|
Cacciotti et al14 | 35 | None | 36 weeks | β-blocker | LSCS live birth |
Gowda et al15 | 29 | None | 38 weeks | Spontaneous cardioversion | Normal |
Walsh et al11 | 41 | None | 35 weeks | Flecainide | Normal |
Kuczkowski16 | 26 | None | During LSCS | Spontaneous | LSCS |
Parasuraman et al4 | 39 | None | 33 weeks during treatment for threatened labour with nifedipine | DCCV | Normal |
Arimie5 | 24 | None | 34 weeks during treatment for premature labour with terbutaline | Diltiazem, digoxin, esmolol, then DCCV | Normal |
Carson et al6 | 30 | None | 35 weeks (twins) during treatment for premature labour with terbutaline | Digoxin, diltiazem, esmolol, procainamide | Normal twins |
Lashgari et al7 | 20 | None | 31 weeks during treatment for premature labour with terbutaline | Diltiazem | (Baby not born at time of publication) |
DCCV, direct current cardioversion; LSCS, lower segment caesarian section.